Global Rheumatology Therapeutics Market (By Drug Types- Disease Modifying Anti-Rheumatic Drugs, Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs, Immunosuppressant Drugs, and Biologics. By Disease Types- Rheumatoid Arthritis, Gout, Osteoarthritis, Juvenile Idiopathic Arthritis, Scleroderma, Sjogren’s Syndrome, and others. By Method of Administration- Topical, Oral, and Parenteral Administration. By Distribution Channel- Hospital, Online, Retail, and others.) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 – 2025
The report covers the analysis and forecast of the rheumatology therapeutics market on global as well as regional level. The study provides historic data of 2016 along with the forecast for the period between 2017 and 2025 based on revenue (US$ Mn).
The study provides a detailed view of the rheumatology therapeutics market, by segmenting it based on by drug types, by disease types, by method of administration, by distribution channel, and regional demand. The rise in geriatric population propels the growth of the rheumatology therapeutics market. Growing awareness about the nature of rheumatology therapy is another prime factor driving the market demand. Additionally, swift acceptance of new drugs for treatment of different types of rheumatic diseases fuels the demand of this market.
Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The segmentation also includes by drug types, by disease types, by method of administration, by distribution channel in all regions. These include different business strategies adopted by the leading players and their recent developments.
A comprehensive analysis of the market dynamics that is inclusive of market drivers, restraints, and opportunities is part of the report. Additionally, the report includes potential opportunities in the Rheumatology therapeutics market at the global and regional levels. Market dynamics are the factors which impact the market growth, so their analysis helps understand the ongoing trends of the global market. Therefore, the report provides the forecast of the global market for the period from 2017 to 2025, along with offering an inclusive study of the rheumatology therapeutics market.
The report provides the size of the Rheumatology therapeutics market in 2017 and the forecast for the next eight years up to 2025. The size of the global rheumatology therapeutics market is provided in terms of revenue. Market revenue is defined in US$ Mn. The market dynamics prevalent in North America, Europe, Asia Pacific, Middle East and Africa and Latin America has been considered in estimating the growth of the global market.
Market estimates for this study have been based on revenue being derived through regional pricing trends. The Rheumatology therapeutics market has been analyzed based on expected demand. Bottom-up approach is done to estimate the global revenue of the rheumatology therapeutics market, split into regions. Based on drug types, disease types, method of administration, and by distribution channel the individual revenues from all the regions is summed up to achieve the global revenue for rheumatology therapeutics. Companies were considered for the market share analysis, based on their innovation and application and revenue generation. In the absence of specific data related to the sales of rheumatology therapeutics several privately held companies, calculated assumptions have been made in view of the company’s penetration and regional presence.
The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global market. Key players profiled in the report include Sanofi A.G., Takeda Pharmaceutical, AbbVie Inc., Pfizer Inc., Regeneron, Amgen Inc., and few others.
The global rheumatology therapeutics market has been segmented into:
Global Rheumatology Therapeutics Market: By Drug Types
The study provides a detailed view of the rheumatology therapeutics market, by segmenting it based on by drug types, by disease types, by method of administration, by distribution channel, and regional demand. The rise in geriatric population propels the growth of the rheumatology therapeutics market. Growing awareness about the nature of rheumatology therapy is another prime factor driving the market demand. Additionally, swift acceptance of new drugs for treatment of different types of rheumatic diseases fuels the demand of this market.
Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The segmentation also includes by drug types, by disease types, by method of administration, by distribution channel in all regions. These include different business strategies adopted by the leading players and their recent developments.
A comprehensive analysis of the market dynamics that is inclusive of market drivers, restraints, and opportunities is part of the report. Additionally, the report includes potential opportunities in the Rheumatology therapeutics market at the global and regional levels. Market dynamics are the factors which impact the market growth, so their analysis helps understand the ongoing trends of the global market. Therefore, the report provides the forecast of the global market for the period from 2017 to 2025, along with offering an inclusive study of the rheumatology therapeutics market.
The report provides the size of the Rheumatology therapeutics market in 2017 and the forecast for the next eight years up to 2025. The size of the global rheumatology therapeutics market is provided in terms of revenue. Market revenue is defined in US$ Mn. The market dynamics prevalent in North America, Europe, Asia Pacific, Middle East and Africa and Latin America has been considered in estimating the growth of the global market.
Market estimates for this study have been based on revenue being derived through regional pricing trends. The Rheumatology therapeutics market has been analyzed based on expected demand. Bottom-up approach is done to estimate the global revenue of the rheumatology therapeutics market, split into regions. Based on drug types, disease types, method of administration, and by distribution channel the individual revenues from all the regions is summed up to achieve the global revenue for rheumatology therapeutics. Companies were considered for the market share analysis, based on their innovation and application and revenue generation. In the absence of specific data related to the sales of rheumatology therapeutics several privately held companies, calculated assumptions have been made in view of the company’s penetration and regional presence.
The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global market. Key players profiled in the report include Sanofi A.G., Takeda Pharmaceutical, AbbVie Inc., Pfizer Inc., Regeneron, Amgen Inc., and few others.
The global rheumatology therapeutics market has been segmented into:
Global Rheumatology Therapeutics Market: By Drug Types
- Disease Modifying Anti-Rheumatic Drugs
- Corticosteroids
- Non-Steroidal Anti-Inflammatory Drugs
- Immunosuppressant Drugs
- Biologics
- Rheumatoid Arthritis
- Gout
- Osteoarthritis
- Juvenile Idiopathic Arthritis
- Scleroderma
- Sjogren’s Syndrome
- Others
- Topical
- Oral
- Parenteral
- Hospital
- Online
- Retail
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- France
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Rest of Asia Pacific
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
- Latin America
- Brazil
- Rest of Latin America
1 INTRODUCTION
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF RHEUMATOLOGY THERAPEUTICS MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SNAPSHOT
3.2 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET REVENUE, 2017– 2025(US$ MN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DRUG TYPES
5.1 OVERVIEW
5.2 DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
5.3 CORTICOSTEROIDS
5.4 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
5.5 IMMUNOSUPPRESSANT DRUGS
5.6 BIOLOGICS
6 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DISEASE TYPE
6.1 OVERVIEW
6.2 RHEUMATOID ARTHRITIS
6.3 GOUT
6.4 OSTEOARTHRITIS
6.5 JUVENILE IDIOPATHIC ARTHRITIS
6.6 SCLERODERMA
6.7 SJOGREN’S SYNDROME
6.8 OTHERS
7 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY METHOD OF ADMINISTRATION
7.1 OVERVIEW
7.2 TOPICAL
7.3 ORAL
7.4 PARENTERAL
8 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
8.1 HOSPITAL
8.2 ONLINE
8.3 RETAIL
8.4 OTHERS
9 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY GEOGRAPHY
9.1 NORTH AMERICA
9.1.1 MARKET DYNAMICS
9.1.1.1 DRIVERS
9.1.1.2 RESTRAINS
9.1.1.3 OPPORTUNITY
9.1.2 U.S.
9.1.3 CANADA
9.1.4 MEXICO
9.2 EUROPE
9.2.1 MARKET DYNAMICS
9.2.1.1 DRIVERS
9.2.1.2 RESTRAINS
9.2.1.3 OPPORTUNITY
9.2.2 U.K.
9.2.3 FRANCE
9.2.4 GERMANY
9.2.5 SPAIN
9.2.6 REST OF EUROPE
9.3 ASIA PACIFIC
9.3.1 MARKET DYNAMICS
9.3.1.1 DRIVERS
9.3.1.2 RESTRAINS
9.3.1.3 OPPORTUNITY
9.3.2 INDIA
9.3.3 CHINA
9.3.4 JAPAN
9.3.5 REST OF ASIA PACIFIC
9.4 MIDDLE EAST AND AFRICA
9.4.1 MARKET DYNAMICS
9.4.1.1 DRIVERS
9.4.1.2 RESTRAINS
9.4.1.3 OPPORTUNITY
9.4.2 SOUTH AFRICA
9.4.3 REST OF MIDDLE EAST AND AFRICA
9.5 LATIN AMERICA
9.5.1 MARKET DYNAMICS
9.5.1.1 DRIVERS
9.5.1.2 RESTRAINS
9.5.1.3 OPPORTUNITY
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA
10 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY COMPANY
10.1 INTRODUCTION
10.2 SANOFI S.A.
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS & SERVICES
10.2.3 KEY STRATEGY
10.2.4 RECENT DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.3 TAKEDA PHARMACEUTICAL
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS & SERVICES
10.3.3 KEY STRATEGY
10.3.4 RECENT DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.4 ABBVIE INC.
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS & SERVICES
10.4.3 KEY STRATEGY
10.4.4 RECENT DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.5 REGENERON PHARMACEUTICALS INC.
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS & SERVICES
10.5.3 KEY STRATEGY
10.5.4 RECENT DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.6 NOVARTIS AG
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS & SERVICES
10.6.3 KEY STRATEGY
10.6.4 RECENT DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.7 AMGEN INC.
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS & SERVICES
10.7.3 KEY STRATEGY
10.7.4 RECENT DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.8 JANSSEN BIOTECH INC.
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS & SERVICES
10.8.3 KEY STRATEGY
10.8.4 RECENT DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.9 PFIZER INC.
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS & SERVICES
10.9.3 KEY STRATEGY
10.9.4 RECENT DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.10 BRISTOL-MYERS SQUIBB COMPANY
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS & SERVICES
10.10.3 KEY STRATEGY
10.10.4 RECENT DEVELOPMENTS
10.10.5 SWOT ANALYSIS
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF RHEUMATOLOGY THERAPEUTICS MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SNAPSHOT
3.2 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET REVENUE, 2017– 2025(US$ MN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DRUG TYPES
5.1 OVERVIEW
5.2 DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
5.3 CORTICOSTEROIDS
5.4 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
5.5 IMMUNOSUPPRESSANT DRUGS
5.6 BIOLOGICS
6 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DISEASE TYPE
6.1 OVERVIEW
6.2 RHEUMATOID ARTHRITIS
6.3 GOUT
6.4 OSTEOARTHRITIS
6.5 JUVENILE IDIOPATHIC ARTHRITIS
6.6 SCLERODERMA
6.7 SJOGREN’S SYNDROME
6.8 OTHERS
7 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY METHOD OF ADMINISTRATION
7.1 OVERVIEW
7.2 TOPICAL
7.3 ORAL
7.4 PARENTERAL
8 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
8.1 HOSPITAL
8.2 ONLINE
8.3 RETAIL
8.4 OTHERS
9 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY GEOGRAPHY
9.1 NORTH AMERICA
9.1.1 MARKET DYNAMICS
9.1.1.1 DRIVERS
9.1.1.2 RESTRAINS
9.1.1.3 OPPORTUNITY
9.1.2 U.S.
9.1.3 CANADA
9.1.4 MEXICO
9.2 EUROPE
9.2.1 MARKET DYNAMICS
9.2.1.1 DRIVERS
9.2.1.2 RESTRAINS
9.2.1.3 OPPORTUNITY
9.2.2 U.K.
9.2.3 FRANCE
9.2.4 GERMANY
9.2.5 SPAIN
9.2.6 REST OF EUROPE
9.3 ASIA PACIFIC
9.3.1 MARKET DYNAMICS
9.3.1.1 DRIVERS
9.3.1.2 RESTRAINS
9.3.1.3 OPPORTUNITY
9.3.2 INDIA
9.3.3 CHINA
9.3.4 JAPAN
9.3.5 REST OF ASIA PACIFIC
9.4 MIDDLE EAST AND AFRICA
9.4.1 MARKET DYNAMICS
9.4.1.1 DRIVERS
9.4.1.2 RESTRAINS
9.4.1.3 OPPORTUNITY
9.4.2 SOUTH AFRICA
9.4.3 REST OF MIDDLE EAST AND AFRICA
9.5 LATIN AMERICA
9.5.1 MARKET DYNAMICS
9.5.1.1 DRIVERS
9.5.1.2 RESTRAINS
9.5.1.3 OPPORTUNITY
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA
10 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY COMPANY
10.1 INTRODUCTION
10.2 SANOFI S.A.
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS & SERVICES
10.2.3 KEY STRATEGY
10.2.4 RECENT DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.3 TAKEDA PHARMACEUTICAL
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS & SERVICES
10.3.3 KEY STRATEGY
10.3.4 RECENT DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.4 ABBVIE INC.
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS & SERVICES
10.4.3 KEY STRATEGY
10.4.4 RECENT DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.5 REGENERON PHARMACEUTICALS INC.
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS & SERVICES
10.5.3 KEY STRATEGY
10.5.4 RECENT DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.6 NOVARTIS AG
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS & SERVICES
10.6.3 KEY STRATEGY
10.6.4 RECENT DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.7 AMGEN INC.
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS & SERVICES
10.7.3 KEY STRATEGY
10.7.4 RECENT DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.8 JANSSEN BIOTECH INC.
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS & SERVICES
10.8.3 KEY STRATEGY
10.8.4 RECENT DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.9 PFIZER INC.
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS & SERVICES
10.9.3 KEY STRATEGY
10.9.4 RECENT DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.10 BRISTOL-MYERS SQUIBB COMPANY
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS & SERVICES
10.10.3 KEY STRATEGY
10.10.4 RECENT DEVELOPMENTS
10.10.5 SWOT ANALYSIS
